AI Protein Design
AI-Driven Protein Therapeutics
How generative AI creates new mechanisms for immune disease
Evozyne builds therapeutic proteins that natural evolution never produced. Our platform uses generative AI and high-throughput biology to design, build, and validate proteins with properties tailored to immune-mediated diseases with high unmet need.
Why AI-native matters
Traditional protein engineering fine-tunes what biology already invented. Evozyne starts from first principles. Our models learn how sequence drives function across large protein families and use that insight to design proteins with new capabilities. This creates therapeutic space beyond antibodies and small molecules.
Key advantages:
- Precision control of activity, specificity, and signaling
- Designed-in stability and reduced immunogenicity
- Rapid iteration cycles that compress discovery timelines
- Mechanisms not constrained by natural evolution
EvoGen: Generative Protein Design
EvoGen integrates transformer-based architectures and variational autoencoding to map sequence-to-function relationships at scale. The model predicts how sequence changes shift potency, stability, and immune interactions.
EvoGen creates design-ready sequences that meet multiple therapeutic criteria in a single pass, enabling programs that traditional engineering can’t reach.
EvoLab: High-Throughput Experimental Validation
EvoLab tests thousands of designed proteins each cycle. Activity, specificity, biophysical properties, and immunogenicity are measured directly. These datasets feed back into EvoGen, increasing its predictive accuracy over time.
This closed-loop system makes the platform stronger with every iteration.
Validated Performance
Peer-reviewed publications demonstrate how Evozyne’s AI engine produces proteins with major performance gains:
- PNAS: ProT-VAE, developed with NVIDIA, delivered large improvements in catalytic activity and stability.
- microPublication Biology: ML-guided design created synthetic proteins with higher thermotolerance than natural variants.
These studies show that generative AI can create high-function proteins suitable for therapeutic development.
Applications in Immunology
Evozyne focuses on immune-mediated diseases where current therapies fall short. Engineered proteins offer advantages over antibodies and small molecules, including tunable mechanisms, improved durability, and reduced off-target effects.
Our early modalities include:
- Selective IgG proteases that target pathogenic IgG
- Engineered cytokines that separate therapeutic signaling from inflammatory toxicity
Each modality highlights how AI-driven design can reshape disease biology.
A Platform Built to Scale
Because Evozyne designs protein families rather than isolated molecules, each discovery cycle unlocks new therapeutic possibilities. The engine expands pipeline potential as the model learns, creating multiple shots on goal for partners and investors.